Heart, Lung and Circulation
Volume 17, Issue 6 , Pages 451-462 , December 2008

Molecular Profiling of Non-Small Cell Lung Cancer: Of What Value in Clinical Practice?

  • Genni M. Newnham, FRACP

      Affiliations

    • Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia
    • ,
  • David M. Thomas, FRACP

      Affiliations

    • Ian Potter Foundation, Centre for Cancer Genomics and Predictive Medicine and Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia
    • ,
  • Sue Anne McLachlan, FRACP

      Affiliations

    • Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia
    • ,
  • Gavin Wright, FRACS

      Affiliations

    • Cardiothoracic Care Centre, St Vincent's Hospital, Melbourne, Australia
    • Corresponding Author InformationCorresponding author at: East Melbourne Heart & Lung, 55 Victoria Parade, Fitzroy, VIC 3065, Australia. Tel.: +61 3 9415 8329; fax: +61 3 9417 1694.
    • ,
  • Matthew Conron, FRACP

      Affiliations

    • Department of Respiratory Medicine, St Vincent's Hospital, Melbourne, Australia

Received 23 May 2007 ,Accepted 14 November 2007.

References 

  1. Cancer Council Victoria . Lung cancer. Canstat. 2002;36
  2. Murren J, Glatstein E, Pass H. Small cell lung cancer. In:  DeVita V,  Hellman S,  Rosenberg S editor. Cancer—principles and practice of oncology. Lippincott: Williams & Wilkins; 2001;p. 983–1018
  3. Shepherd F, Periera J, Ciuleanu T. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  4. Shepherd F, Pereira J, Ciuleanu TE, Tan EH, Hirsh S, Thongprasert S, et al. A randomised placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol. 2004;23;[Abstract 7022]
  5. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II rial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21(12):2237–2246
  6. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–2158
  7. Natale R, Skarin A, Maddox A-M. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in IDEAL 2. Proc Am Soc Clin Oncol. 2002;21:292a;[Abstract 1167]
  8. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3228–3247
  9. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with Erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(7):1–7
  10. Pignon J, Tribodet H, Scagliotti G, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients.. J Clin Oncol 2006 ASCO Annu Meet Proc, Part 1. 2006;24(18S):7008
  11. Pao W, Miller V. Epidermal growth factor receptor mutations, small molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556–2568
  12. Ciardiello F, Caputo R, Bianco R. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1893 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053–2063
  13. Sirotnak F, Zakowski M, Miller V. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885–4892
  14. She Y, Lee F, Chen J. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumours in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res. 2003;9:3773–3778
  15. Williams K, Telfer B, Stratford I. ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 2002;86:1157–1161
  16. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, et al. Antitumour activity of erlotinib (OSI-774 Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs. 2004;15(5):503–512
  17. Herbst R, Prager D, Hermann R. TRIBUTE: A phase III trial of erlotinib (OS-774) combined with carboplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2005;23:5892–5899
  18. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase II trial—INTACT 2. J Clin Oncol. 2004;22(5):785–794
  19. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol. 2004;22(5):777–784
  20. Gatzemeier U, Pluzanska A, Szczesna A. Results of a phase II trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2004;22(619s):[Abstract 7010]
  21. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol. 2003;21(33):4342–4349
  22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Ross A, Okimoto BS, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139
  23. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500
  24. Pusztai L, Ayers M, Stec J, Hortobagyi G. Clinical application of cDNA microarrays in oncology. Oncologist. 2003;8:252–258
  25. Georges M, Coppieters W, Charlier C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Curr Opin Genet Dev. 2007;
  26. Holloway AJ, van Laar R, Tothill R, Bowtell DDL. Options available—from start to finish—for obtaining data from DNA microarrays II. Nat Genet. 2002;32s:481–489
  27. Ramaswamy S, Golub T. DNA microarrays in clinical oncology. J Clin Oncol. 2002;20(7):1932–1941
  28. Lipshutz R, Fodor S, Gingeras T, Lockhart D. High density synthetic oligonucleotide arrays. Nat Genet. 1999;21:20–24
  29. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams C, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999;23(1):41–46
  30. Pinkel D, Segraves R, Sudar S, Clark S, Poole I, Kowbel D, et al. High resolution analysis of DNA copy number variation in breast cancer using comparative genomic hybridization to DNA microarrays. Nat Genet. 1998;20:207–211
  31. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, et al. Quanitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 2000;25(2):144–146
  32. Albertson D, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet. 2003;12:145–152
  33. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001;29(3):263–264
  34. Chen Q, Bilke S, Javed K. High-resolution cDNA micro-array based comparative genomic hybridization analysis in neuroblastoma. Cancer Lett. 2005;228:71–81
  35. Ishkanian AS, Mallof CA, Watson SK, DeLeeuw RJ, Chi B, Snijders AM, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet. 2004;36(3):299–303
  36. Scharp R, Ting J, Pevsner J, Ruczinski I. SNPchip: R classes and methods for SNP array data. Bioinformatics. 2007;23(5):627–628
  37. Jiang H, Deng Y, Chen H. Joint analysis if two microarray gene-expression data sets to select lung adenocarcinoma marker genes. BMC Bioinform. 2004;5:81
  38. Parmigiani G, Garrett-Mayer E, Anbazhagan R. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res. 2004;10.:2922–2927
  39. Garber M, Troyanskaya O, Schluens K. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784–13789
  40. Bhattacharjee A, Richards W, Staunton J. Classification of human lung adenocarcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790–13795
  41. Garnis C, Lockwood W, Vucic E, Ge Y, Girard L, Minna J, et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer. 2006;118:1556–1564
  42. Kikuchi T, Daigo Y, Katagiri T. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph node metastasis and sensitivity to anticancer drugs. Oncogene. 2003;22:2192–2205
  43. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin KV, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridisation: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002;62(13):3636–3640
  44. Beer D, Kardia S, Huang C-C, Giordano T, Levin A, Misek D, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816–824
  45. Ten Have-Opbroek A, Benfield J, van Krieken J, Dijkman J. The alveolar type II cell is a pluripotent stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas. Histol Histopathol. 1997;12(2):319–336
  46. Kim TM, Yim SH, Lee JS, Kwon MS, Ryu JW, Kang HM, et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res. 2005;11(23):8235–8242
  47. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA. 2005;102.:9625–9630
  48. Ramaswamy S, Ross K, Lander E, Golub T. A molecular signature of metastasis in primary solid tumours. Nat Genet. 2003;33:49–54
  49. Wigle D, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002;62:3005–3008
  50. Potti A, Mukherjee S, Petersen R, Dressman H, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med. 2006;355:570–580
  51. Chen H, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356(1):11–20
  52. Dupuy A, Simon R. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99:147–157
  53. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res. 2005;11(17):6177–6185
  54. Peng WX, Shibata T, Katoh H, Kokubu A, Matsuno Y, Asamura H, et al. Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumours of the lung. Cancer Sci. 2005;96(10):661–667
  55. Dan S, Tsunoda T, Tanaka T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002;62:1139–1147
  56. Staunton J, Slonim D, Coller H. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA. 2001;98:10787–10792
  57. Zembutsu H, Ohnishi Y, Tsunoda T. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002;62:518–527
  58. Sweet-Cordero A, Muhkerjee S, Subramanian A. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2005;37:48–55
  59. Balko J, Potti A, Saunders C, Stromberg A, Haura E, Black E. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumours. BMC Genom. 2006;7:289–303
  60. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–13311
  61. Thomas R, Weir B, Meyerson M. Genomic approaches to lung cancer. Clin Cancer Res. 2006;12(Suppl. 14):4384s–4391s
  62. Amann J, Kalyankrishna S, Massion P. Aberrant epidermal growth factor receptor signalling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226–235
  63. Bell D, Lynch H, Haserlat S. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081–8092
  64. Capuzzo F, Hirsch F, Rossi E. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–655
  65. Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133–144
  66. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006;24(14):2158–2163
  67. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63(21):7113–7121
  68. Garnis C, Campbell J, Davies J, Lam S, Lam W. Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. Hum Mol Genet. 2005;14(4):475–482
  69. Garnis C, Davies JJ, Buys TP, Tsao MS, MacAulay C, Lam S, et al. Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene. 2005;24(30):4806–4812
  70. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 1997;57(12):2331–2335
  71. Bjorkqvist AM, Husqafvel-Pursiainen K, Anttila S, Karjalainen A, Tammilehto L, Mattson K, et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromos Cancer. 1998;22(1):79–82
  72. Pei J, Balsara BR, Li W, Litwin S, Garbrielson E, Feder M, et al. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromos Cancer. 2001;31(3):282–287
  73. Balsara B, Testa J. Chromosomal imbalances in human lung cancer. Oncogene. 2002;21(45):6877–6883
  74. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman S, Whitehead R, et al. The phosphatidylinositol 3-kinase p85alpha gene is an oncogene in human ovarian and colon tumours. Cancer Res. 2001;61:7426–7429
  75. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99–102
  76. Singh B, Stoffel A, Gogineni S, Poluri A, Pfister DG, Shaha AR, et al. Amplification of the 3q26 3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol. 2002;161(2):365–371
  77. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med. 2004;170(10):1088–1094
  78. Tinker A, Boussioutas A, Bowtell DDL. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell. 2006;9:333–339
  79. Jiang F, Yin Z, Caraway N, Li R, Katz R. Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridisation analysis of cDNA microarrays. Neoplasia. 2004;6(5):623–635

PII: S1443-9506(08)00171-6

doi: 10.1016/j.hlc.2007.11.144

Heart, Lung and Circulation
Volume 17, Issue 6 , Pages 451-462 , December 2008

Article Tools

* Image Usage & Resolution